TG Therapeutics Ukoniq’s Future In Doubt Amidst Scrutiny Of P13K Inhibitor Accelerated Approvals

 
• By Bridget Silverman
  
GREEN BLURRY BUBBLES
The risk profile of the leukemia and lymphoma therapies are blurry after FDA's drug safety communication. • Source: Alamy

More from Review Pathways

More from Pathways & Standards